drugset / Trial / NCT00756860
A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if subjects on 2g AMG 223 will achieve 60% or greater reduction in urinary phosphorus from baseline compared to subjects on 2g Renagel®. Renagel®, Sevelamer HCl is currently the market leader for the treatment of hyperphosphatemia in patients on dialysis.
Timeline
- Start
- 2008-05
- Primary completion
- 2008-08
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bixalomer | Small molecule | 2 g | — |
| Comparator | Sevelamer | Other / unclassified | 2 g | — |
Indications
No indication recorded.